๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
NCT06728865Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
Li-kun Chen
Phase 2
70
Guangzhou
2024-09-04
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
NCT06635798Tetanus
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
582
Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Wuhan, Hengyang
2024-09-03
Recruiting
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xiโ€™an
2024-09-03
Recruiting
Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
NCT07648069Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Active, closed
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
NCT07230080HCC - Hepatocellular Carcinoma, SBRT, TACE, Immunotherapy
Nanfang Hospital, Southern Medical University
Observational
17
Guangzhou
2024-09-01
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
OSAHS Screening in Diverse Populations
NCT07736872Obstructive Sleep Apnea (OSA), Snoring, Prevalence, Questionnaires and Surveys
Kang Wu
Observational
100,000
Guangzhou, Anshun
2024-09-01
Recruiting
Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis
NCT06301373Rheumatoid Arthritis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
130
Foshan, Guangzhou, Jieyang, Shantou
2024-09-01
Recruiting
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
NCT06607770Lung Cancer
Zhou Chengzhi
Phase 1/2
20
Guangzhou
2024-09-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Recruiting
A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
NCT06718972Meningeal Metastasis, Non-Small Cell Lung Cancer
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
By invitation
A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
NCT06647264Hepatocellular Carcinomas, Cholecystectomy, Laparoscopic, Hepatectomy, Pancreatoduodenectomy
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2024-09-01
Not yet open
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
NCT06567600Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2
43
Guangzhou
2024-09-01
Recruiting
Modified Orbital Decompression in the Treatment of Moderate-to-severe Grave's Ophthalmopathy
NCT06588764Graves Ophthalmopathy, Surgery
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09
Not yet open
Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
NCT06585059Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-09
Active, closed
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC
NCT07530276NSCLC
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Recruiting
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
NCT06514027Non Small Cell Lung Cancer
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
Nd:YAG Laser Effects on Subgingival Microbiota in Stage III-IV Periodontitis
NCT07061756Periodontitis
Rui He
Not applicable
240
Guangzhou
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Active, closed
Validity and Reliability of the Mastitis Symptom Severity Assessment Methods (M-Score and BISSI) in Non-Lactational Mastitis
NCT06667609Granulomatous Mastitis, Mastitis Chronic
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
320
Chaozhou, Dongguan, Guangzhou, Jiangmen, Shanwei
2024-08-28
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
NCT06561178Esophageal Squamous Cell Carcinoma
Sun Yat-Sen University Cancer Center
Observational
50
Guangzhou
2024-08-26
Not yet open
Safety and Efficacy of Degradable Magnesium Metal Clips in Surgical Margins of Radical Surgery for Malignant Bone and Soft Tissue Tumors
NCT06550765Sarcoma, Soft Tissue, Sarcoma, Spindle Cell
Guangdong Provincial People's Hospital
Not applicable
98
Guangzhou
2024-08-25
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xiโ€™an, Beijing, Shanghai
2024-08-22
Recruiting
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861Acute Myeloid Leukemia
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jiazhuang, Jinan
2024-08-21
Recruiting
Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
NCT06622798Exploring the Correlation of HRD Score Pairs with the Prognosis of Chinese Ovarian Cancer Patients and the Outcome of Maintenance Therapy with PARPi
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
470
Guangzhou
2024-08-20
Recruiting
Treatment of Mandibular Bone Cyst by Navigation and Endoscopy
NCT06567535Jaw Cysts
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
122
Guangzhou
2024-08-20
Active, closed
Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
NCT06531512Diabetic Foot Ulcer
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Active, closed
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC๏ผša Pilot Study
NCT06461338Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
Not applicable
60
Guangzhou, Nanjing
2024-08-15
Recruiting
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
NCT07188441GCT, Germ Cell Tumor, Central Malignant Germ Cell Tumor
Chengcheng Guo
Phase 2
40
Guangzhou
2024-08-13
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC
NCT06727162Head and Neck Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
100
Guangzhou
2024-08-13
Recruiting
Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
NCT06503692Arteriovenous Graft Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
Clinical Study of Radical Right Hemicolectomy Versus Radical Right Hemicolectomy Combined with Indocyanine Green Fluorescence Imaging Lymphatic Tracer Dissection for the Treatment of Right Colon Cancer
NCT06485609Colon Cancer
Sun Yat-sen University
Not applicable
1,200
Guangzhou
2024-08-10
Recruiting
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
NCT06506838Soft Tissue Sarcoma, Doxorubicin, Radiotherapy
Guangdong Provincial People's Hospital
Phase 4
39
Guangzhou
2024-08-10
Recruiting
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN๏ผˆFIM๏ผ‰
NCT06877234Essential Hypertension
Shenzhen Pulsecare Medical Technology Co., Ltd.
Not applicable
6
Guangzhou
2024-08-08
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
NCT06574347Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 2
120
Guangzhou
2024-08-07
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Active, closed
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
NCT06500026Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Active, closed
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014Osteoporosis
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
By invitation
The Effects and Neural Mechanisms of Vitamin D and Iron-Immune Homeostasis on Inhibitory Control in Obsessive-Compulsive Disorder
NCT07763977Obsessive Compulsive Disorder (OCD)
Guangdong Provincial People's Hospital
Not applicable
60
Guangzhou
2024-08-06
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
NCT06611150Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Active, closed
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
NCT06282874Carcinoma, Non-Small-Cell Lung, Brain Metastases, Leptomeningeal Metastasis
Guangdong Association of Clinical Trials
Phase 4
41
Dongguan, Foshan, Guangzhou
2024-08-01
Recruiting
Association of Lifestyle With Complications in the Diabetic Population
NCT06903364Diabetes Mellitus
Nanfang Hospital, Southern Medical University
Observational
800
Guangzhou
2024-08-01
Recruiting
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
NCT06533384Triple-negative Breast Cancer
Guangdong Provincial People's Hospital
Phase 3
310
Guangzhou
2024-08-01
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Not yet open
Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection
NCT06526455Ulcers, Gastric
Shicai Ye
Phase 4
196
Guangzhou, Maoming, Sanmenxia
2024-08-01
Not yet open
Stem Cell Derived Exome for Treatment of Diabetic Foot
NCT06480123Diabetic Foot, Stem Cell
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2
50
Guangzhou
2024-08-01
Recruiting
Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.
NCT06912815Crohn Disease (CD)
Xiang Gao
Not applicable
184
Guangzhou
2024-08-01
Recruiting
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
NCT06492395Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
178
Guangzhou
2024-08-01
Recruiting
Tranexamic Acid in Patients With Traumatic Bleeding Based on Dynamic Monitoring of Thromboelastography
NCT06736860Trauma Coagulopathy
Nanfang Hospital, Southern Medical University
Phase 4
580
Guangzhou
2024-08-01
Recruiting
Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
NCT06716073Breast Cancer Invasive
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
1,380
Guangzhou, Shantou
2024-08-01
Recruiting
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
NCT06545747Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Recruiting
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
NCT06517511Diffuse Large B Cell Lymphoma
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)
NCT06516822Long-standing Persistent Atrial Fibrillation, Ablation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xiโ€™an
2024-07-31
Active, closed
SAVE-PCI: NyokAssistโ„ข Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Recruiting
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
NCT06308952Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke
Duan Chuanzhi
Phase 4
354
Guangzhou
2024-07-30
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Recruiting
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
NCT06423235Thyroid Nodule
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Recruiting
Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis
NCT06517979Cancer, Lymphatic Metastasis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
10,000
Guangzhou
2024-07-26
Recruiting
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer
NCT06407518Preoperative, Sleep Disturbance, Anxiety, Midazolam
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
280
Guangzhou
2024-07-24
Recruiting
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
NCT06529549Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150Vasodilatory Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
446
Bengbu, Beijing, Guangzhou, Guanzhou, Liuzhou, Xingtai, Luoyang, Wuhan
2024-07-22
Recruiting
Born In Guangzhou Intervention Study
NCT05503849Pregnancy Outcomes, Child Development, Pregnancy Complications
Guangzhou Women and Children's Medical Center
Not applicable
1,160
Guangzhou
2024-07-22
Not yet open
Plasmodium Immunotherapy for Advanced Ovarian Cancer
NCT05924776Advanced Ovarian Cancer
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Phase 2/3
30
Guangzhou
2024-07-20
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
Recruiting
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
NCT06547203Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06475131Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Guangzhou
2024-07-18
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Recruiting
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580Generalized Myasthenia Gravis
Vor Biopharma
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Recruiting
Choroidal and Retinal Features in PACD and POAG on OCT and OCTA
NCT07580014Glaucoma, OCTA, Choroid
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
132
Guangzhou
2024-07-16
Rows per page Showing 1701–1800 of 3318
Previous 16 17 18 19 20 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=18

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.